• Wed news: BioNTech buying Biotheus. FDA’s Califf lists hopes for his successor. Amgen loses $12B market cap from hidden spreadsheet tab. TRex Bio raises $84M. London is Europe’s life science capitol. See more on our front page

SURPASS canned

Anonymous

Guest
"physicians were uncomfortable switching from Copaxone to Tysabri or Rebif to Tysabri without trying the other agents."

It's only your life....why not roll the dice? Come on people!